Axsome Therapeutics/AXSM

$75.19

1.36%
-
1D1W1MYTD1YMAX

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Ticker

AXSM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Herriot Tabuteau

Employees

545

Headquarters

New york, United States

AXSM Metrics

BasicAdvanced
$3.6B
Market cap
-
P/E ratio
-$6.38
EPS
1.25
Beta
-
Dividend rate
$3.6B
1.25106
$98.40
$55.02
674K
3.197
3.089
125.237
125.237
-55.54%
-63.4%
-231.68%
-85.88%
14.227
24.778
44.475
73.58%
-67.94%

What the Analysts think about AXSM

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 15 analysts.
60.75% upside
High $190.00
Low $50.00
$75.19
Current price
$120.87
Average price target

AXSM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-91.18% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$75M
4.76%
Net income
-$68M
-30.73%
Profit margin
-91.18%
-33.88%

AXSM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 19.56%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.54
-$1.32
-$2.08
-$1.44
-
Expected
-$1.22
-$1.20
-$1.17
-$1.20
-$1.33
Surprise
25.98%
9.67%
77.59%
19.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Axsome Therapeutics stock?

Axsome Therapeutics (AXSM) has a market cap of $3.6B as of May 28, 2024.

What is the P/E ratio for Axsome Therapeutics stock?

The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of May 28, 2024.

Does Axsome Therapeutics stock pay dividends?

No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Axsome Therapeutics dividend payment date?

Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Axsome Therapeutics?

Axsome Therapeutics (AXSM) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Axsome Therapeutics stock price target?

The target price for Axsome Therapeutics (AXSM) stock is $120.87, which is 61.33% above the current price of $74.92. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Axsome Therapeutics stock

Buy or sell Axsome Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing